London, Feb 15, 2026, 13:20 GMT — Market closed
- Haleon ended Friday at 409.2 pence, gaining 0.64%.
- Full-year 2025 earnings are set for release on Feb. 25, the company said.
Haleon finished Friday up a touch, settling at 409.2 pence in London. The stock heads into Monday’s open as investors look ahead to the next potential company move.
Haleon is setting the stage for Feb. 25, when it plans to release its full-year 2025 results—an appointment investors are watching closely as they weigh the outlook for growth and margins. The date appears on the company’s investor calendar as well.
This is important: the consumer-health company goes into earnings with uncertainty swirling around North American demand, what’s happening to pricing, and the timing of its cost program filtering through to profit. Traders want clarity on the numbers, though here, the outlook’s tone usually ends up setting the direction.
Shares opened at 405.5 pence and swung from 403.9 to 410.7 pence on Friday. Roughly 24.4 million shares changed hands—more than double the previous day’s volume, which came in near 11.0 million.
Haleon announced back in January that it’s revamping its operating model—rolling out a new Chief Growth Officer position and breaking the company into six separate operating units. The company aims to have the changes in place by mid-2026. Chief executive Brian McNamara said the move “will result in a simpler and more agile and efficient organisation.” Haleon Corporate
The overhaul goes hand-in-hand with an ongoing drive for better productivity. Haleon, for its part, has already flagged 800 million pounds in gross productivity gains over a five-year stretch, linking those savings to its medium-term profit goals, Reuters reported.
Still, risks remain. Back in July, Haleon trimmed its 2025 revenue growth outlook after sluggish sales in North America—its top market—citing softer consumer sentiment and mounting competition. Organic revenue growth, which ignores currency effects and recent acquisitions, was now pegged at roughly 3.5% for the year. Previously, the company had targeted between 4% and 6%. Jefferies analysts didn’t mince words: “The organic sales growth guide cut is more extreme than feared.” Reuters
In October, a follow-up from Reuters pointed to some stabilization. Haleon reported robust Sensodyne sales and better market share in both the U.S. and India, though the consumer environment didn’t get any easier. Still, JPMorgan analysts flagged “the weak U.S. market consumption remains a concern” looking into 2026. Reuters
Looking to the week, investors are zeroed in on Feb. 25 for any clearer read on sales growth and profit guidance, plus some sense of the timeline for the company’s organisational overhaul to show results. Haleon’s results page confirms the Feb. 25 event and a Q&A webcast.
